drugset / Trial / NCT02682238

A Safety, Tolerability and Preliminary Efficacy Study of BBI-4000 Gel in Subjects With Palmar Hyperhidrosis

NCT02682238 ↗

Phase 2 Completed 50 enrolled Botanix Pharmaceuticals
RandomizedParallel-groupQuadruple-blindTreatment

Summary

To assess the safety and local tolerability of BBI-4000 15% gel compared with vehicle (placebo) when applied topically once daily in subjects with palmar hyperhidrosis.

Timeline

Start
2016-03-08
Primary completion
2016-07-14
Completion
2016-10-04

Drugs

EvaluationDrugModalityDoseRoute
Subject SOFPIRONIUM Small molecule 15 % Topical